Derek Maetzold, President and CEO, Castle Biosciences is harnessing the power of genomics to understand the biology of skin cancer. Castle has developed genomic tests to determine how aggressive melanoma and squamous cell carcinoma are in order to better inform dermatologist and patients about intervention decisions. With both diagnostic and prognostic tests and assist from artificial intelligence machine learning-based algorithms, calculations are made for assessing the risk of developing metastatic disease for each individual patient.